From WikiProjectMed
Jump to navigation Jump to search
Drospirenone molecule ball.png
Trade namesAlone: Slynd
With estradiol: Angeliq
With ethinylestradiol: Yasmin, Yasminelle, Yaz, others
Other namesDihydrospirenone; Dihydrospirorenone; 1,2-Dihydrospirorenone; MSp; SH-470; ZK-30595; LF-111; 17β-Hydroxy-6β,7β:15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21-carboxylic acid, γ-lactone
  • (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-Hexadecahydro-10,13-dimetylspiro-[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenantrene-17,2'(5'H)-furan]-3,5'(2H)-dione
Clinical data
Drug classProgestogen; Progestin; Antimineralocorticoid; Steroidal antiandrogen
  • US: X (Contraindicated)
Routes of
By mouth[1]
Legal status
  • In general: ℞ (Prescription only)
Protein binding95–97% (to albumin)[4][1][2]
MetabolismLiver (mostly CYP450-independent (reduction, sulfation, and cleavage of lactone ring), some CYP3A4 contribution)[2][5][6]
Metabolites• Drospirenone acid[4]
• 4,5-Dihydrodrospirenone 3-sulfate[4]
Elimination half-life25–33 hours[4][2][1]
ExcretionUrine, feces[4]
Chemical and physical data
Molar mass366.501 g·mol−1
3D model (JSmol)
  • O=C7O[C@@]6([C@@]3([C@H]([C@@H]2[C@@H]4[C@H](/C1=C/C(=O)CC[C@]1(C)[C@H]2CC3)C4)[C@@H]5C[C@@H]56)C)CC7
  • InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1 checkY

Drospirenone is a progestin medication which is used in birth control pills to prevent pregnancy and in menopausal hormone therapy, among other uses.[1][7] It is available both alone under the brand name Slynd and in combination with an estrogen under the brand name Yasmin among others.[7][4] The medication is taken by mouth.[1]

Common side effects include acne, headache, breast tenderness, weight increase, and menstrual changes.[4] Rare side effects may include high potassium levels and blood clots, among others.[4][8] Drospirenone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone.[1] It has additional antimineralocorticoid and antiandrogenic activity and no other important hormonal activity.[1] Because of its antimineralocorticoid activity and lack of undesirable off-target activity, drospirenone is said to more closely resemble bioidentical progesterone than other progestins.[9][10]

Drospirenone was patented in 1976 and introduced for medical use in 2000.[11][12] It is available widely throughout the world.[7] The medication is sometimes referred to as a "fourth-generation" progestin.[13][14] It is available as a generic medication.[15] In 2017, a formulation of drospirenone with ethinylestradiol was the 98th most commonly prescribed medication in the United States, with more than eight million prescriptions.[16][17]

Medical uses

Drospirenone (DRSP) is used by itself as a progestogen-only birth control pill, in combination with the estrogen ethinylestradiol (EE), with or without supplemental folic acid (vitamin B9), as a combined birth control pill, and in combination with the estrogen estradiol (E2) for use in menopausal hormone therapy.[18] A birth control pill with low-dose ethinylestradiol is also indicated for the treatment of moderate acne, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and dysmenorrhea (painful menstruation).[19][20] For use in menopausal hormone therapy, E2/DRSP is specifically approved to treat moderate to severe vasomotor symptoms (hot flashes), vaginal atrophy, and postmenopausal osteoporosis.[21][22][23][24] The drospirenone component in this formulation is included specifically to prevent estrogen-induced endometrial hyperplasia.[25] Drospirenone has also been used in combination with an estrogen as a component of hormone therapy for transgender women.[26][27]

Studies have found that EE/DRSP is superior to placebo in reducing premenstrual emotional and physical symptoms while also improving quality of life.[28][29] E2/DRSP has been found to increase bone mineral density and to reduce the occurrence of bone fractures in postmenopausal women.[30][25][31][32] In addition, E2/DRSP has a favorable influence on cholesterol and triglyceride levels and decreases blood pressure in women with high blood pressure.[31][32] Due to its antimineralocorticoid activity, drospirenone opposes estrogen-induced salt and water retention and maintains or slightly reduces body weight.[33]

Available forms

Drospirenone is available in the following formulations, brand names, and indications:[34][35]


Contraindications of drospirenone include renal impairment or chronic kidney disease, adrenal insufficiency, presence or history of cervical cancer or other progestogen-sensitive cancers, benign or malignant liver tumors or hepatic impairment, undiagnosed abnormal uterine bleeding, and hyperkalemia (high potassium levels).[4][41][42] Renal impairment, hepatic impairment, and adrenal insufficiency are contraindicated because they increase exposure to drospirenone and/or increase the risk of hyperkalemia with drospirenone.[4]

Side effects

Adverse effects of drospirenone alone occurring in more than 1% of women may include unscheduled menstrual bleeding (breakthrough or intracyclic) (40.3–64.4%), acne (3.8%), metrorrhagia (2.8%), headache (2.7%), breast pain (2.2%), weight gain (1.9%), dysmenorrhea (1.9%), nausea (1.8%), vaginal hemorrhage (1.7%), decreased libido (1.3%), breast tenderness (1.2%), and irregular menstruation (1.2%).[4]

High potassium levels

Drospirenone is an antimineralocorticoid with potassium-sparing properties, though in most cases no increase of potassium levels is to be expected.[41] In women with mild or moderate chronic kidney disease, or in combination with chronic daily use of other potassium-sparing medications (ACE inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, heparin, antimineralocorticoids, or nonsteroidal anti-inflammatory drugs), a potassium level should be checked after two weeks of use to test for hyperkalemia.[41][43] Persistent hyperkalemia that required discontinuation occurred in 2 out of around 1,000 women (0.2%) with 4 mg/day drospirenone alone in clinical trials.[4]

Blood clots

Birth control pills containing ethinylestradiol and a progestin are associated with an increased risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).[44] The incidence is about 4-fold higher on average than in women not taking a birth control pill.[44] The absolute risk of VTE with ethinylestradiol-containing birth control pills is small, in the area of 3 to 10 out of 10,000 women per year, relative to 1 to 5 out of 10,000 women per year not taking a birth control pill.[45][46] The risk of VTE during pregnancy is 5 to 20 in 10,000 women per year and during the postpartum period is 40 to 65 per 10,000 women per year.[46] The higher risk of VTE with combined birth control pills is thought to be due to the ethinylestradiol component, as ethinylestradiol has estrogenic effects on liver synthesis of coagulation factors which result in a procoagulatory state.[8] In contrast to ethinylestradiol-containing birth control pills, neither progestogen-only birth control nor the combination of transdermal estradiol and an oral progestin in menopausal hormone therapy is associated with an increased risk of VTE.[8][47]

Different progestins in ethinylestradiol-containing birth control pills have been associated with different risks of VTE.[8] Birth control pills containing progestins such as desogestrel, gestodene, drospirenone, and cyproterone acetate have been found to have 2- to 3-fold the risk of VTE of birth control pills containing levonorgestrel in retrospective cohort and nested case–control observational studies.[8][45] However, this area of research is controversial, and confounding factors may have been present in these studies.[8][45][48] Other observational studies, specifically prospective cohort and case control studies, have found no differences in risk between different progestins, including between birth control pills containing drospirenone and birth control pills containing levonorgestrel.[8][45][48][49] These kinds of observational studies have certain advantages over the aforementioned types of studies, like better ability to control for confounding factors.[49] Systematic reviews and meta-analyses of all of the data in the mid-to-late 2010s found that birth control pills containing cyproterone acetate, desogestrel, drospirenone, or gestodene overall were associated with a risk of VTE of about 1.3- to 2.0-fold compared to that of levonorgestrel-containing birth control pills.[50][51][45]

Androgenic progestins have been found to antagonize to some degree the effects of ethinylestradiol on coagulation.[52][53][54][55] As a result, more androgenic progestins, like levonorgestrel and norethisterone, may oppose the procoagulatory effects of ethinylestradiol and result in a lower increase in risk of VTE.[8][56] Conversely, this would be the case less or not at all with progestins that are less androgenic, like desogestrel and gestodene, as well as progestins that are antiandrogenic, like drospirenone and cyproterone acetate.[8][56]

In the early 2010s, the FDA updated the label for birth control pills containing drospirenone and other progestins to include warnings for stopping use prior to and after surgery, and to warn that such birth control pills may have a higher risk of blood clots.[42]

Risk of venous thromboembolism (VTE) with hormone therapy and birth control (QResearch/CPRD)
Type Route Medications Odds ratio (95% CI)
Menopausal hormone therapy Oral Estradiol alone
    ≤1 mg/day
    >1 mg/day
1.27 (1.16–1.39)*
1.22 (1.09–1.37)*
1.35 (1.18–1.55)*
Conjugated estrogens alone
    ≤0.625 mg/day
    >0.625 mg/day
1.49 (1.39–1.60)*
1.40 (1.28–1.53)*
1.71 (1.51–1.93)*
Estradiol/medroxyprogesterone acetate 1.44 (1.09–1.89)*
    ≤1 mg/day E2
    >1 mg/day E2
1.18 (0.98–1.42)
1.12 (0.90–1.40)
1.34 (0.94–1.90)
    ≤1 mg/day E2
    >1 mg/day E2
1.68 (1.57–1.80)*
1.38 (1.23–1.56)*
1.84 (1.69–2.00)*
Estradiol/norgestrel or estradiol/drospirenone 1.42 (1.00–2.03)
Conjugated estrogens/medroxyprogesterone acetate 2.10 (1.92–2.31)*
Conjugated estrogens/norgestrel
    ≤0.625 mg/day CEEs
    >0.625 mg/day CEEs
1.73 (1.57–1.91)*
1.53 (1.36–1.72)*
2.38 (1.99–2.85)*
Tibolone alone 1.02 (0.90–1.15)
Raloxifene alone 1.49 (1.24–1.79)*
Transdermal Estradiol alone
   ≤50 μg/day
   >50 μg/day
0.96 (0.88–1.04)
0.94 (0.85–1.03)
1.05 (0.88–1.24)
Estradiol/progestogen 0.88 (0.73–1.01)
Vaginal Estradiol alone 0.84 (0.73–0.97)
Conjugated estrogens alone 1.04 (0.76–1.43)
Combined birth control Oral Ethinylestradiol/norethisterone 2.56 (2.15–3.06)*
Ethinylestradiol/levonorgestrel 2.38 (2.18–2.59)*
Ethinylestradiol/norgestimate 2.53 (2.17–2.96)*
Ethinylestradiol/desogestrel 4.28 (3.66–5.01)*
Ethinylestradiol/gestodene 3.64 (3.00–4.43)*
Ethinylestradiol/drospirenone 4.12 (3.43–4.96)*
Ethinylestradiol/cyproterone acetate 4.27 (3.57–5.11)*
Notes: (1) Nested case–control studies (2015, 2019) based on data from the QResearch and Clinical Practice Research Datalink (CPRD) databases. (2) Bioidentical progesterone was not included, but is known to be associated with no additional risk relative to estrogen alone. Footnotes: * = Statistically significant (p < 0.01). Sources: See template.

Breast cancer

Drospirenone has been found to stimulate the proliferation and migration of breast cancer cells in preclinical research, similarly to certain other progestins.[57][58] However, some evidence suggests that drospirenone may do this more weakly than certain other progestins, like medroxyprogesterone acetate.[57][58] The combination of estradiol and drospirenone has been found to increase breast density, an established risk factor for breast cancer, in postmenopausal women.[59][60][61]

Data on risk of breast cancer in women with newer progestins like drospirenone are lacking at present.[62] Progestogen-only birth control is not generally associated with a higher risk of breast cancer.[62] Conversely, combined birth control and menopausal hormone therapy with an estrogen and a progestogen are associated with higher risks of breast cancer.[63][62][64]


These have been no reports of serious adverse effects with overdose of drospirenone.[4] Symptoms that may occur in the event of an overdose may include nausea, vomiting, and vaginal bleeding.[4] There is no antidote for overdose of drospirenone and treatment of overdose should be based on symptoms.[4] Since drospirenone has antimineralocorticoid activity, levels of potassium and sodium should be measured and signs of metabolic acidosis should be monitored.[4]


Inhibitors and inducers of the cytochrome P450 enzyme CYP3A4 may influence the levels and efficacy of drospirenone.[4] Treatment for 10 days with 200 mg twice daily ketoconazole, a strong CYP3A4 inhibitor among other actions, has been found to result in a moderate 2.0 to 2.7-fold increase in exposure to drospirenone.[4] Drospirenone does not appear to influence the metabolism of omeprazole (metabolized via CYP2C19), simvastatin (metabolized via CYP3A4), or midazolam (metabolized via CYP3A4), and likely does not influence the metabolism of other medications that are metabolized via these pathways.[4] Drospirenone may interact with potassium-sparing medications such as ACE inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, potassium supplements, heparin, antimineralocorticoids, and nonsteroidal anti-inflammatory drugs to further increase potassium levels.[4] This may increase the risk of hyperkalemia (high potassium levels).[4]



Drospirenone binds with high affinity to the progesterone receptor (PR) and mineralocorticoid receptor (MR), with lower affinity to the androgen receptor (AR), and with very low affinity to the glucocorticoid receptor (GR).[1][65][66][3] It is an agonist of the PR and an antagonist of the MR and AR, and hence is a progestogen, antimineralocorticoid, and antiandrogen.[1][65][3][58] Drospirenone has no estrogenic activity and no appreciable glucocorticoid or antiglucocorticoid activity.[1][65][3][58]

Relative affinities (%) of drospirenone and related steroids
Drospirenone 19–70 1–65 0–1 1–6 100–500 0 0
Progesterone 100 0–80 0–1 6–35 100–1000 0 0
Notes: Values are percentages (%). Reference ligands (100%) were progesterone for the PR, metribolone for the AR, estradiol for the ER, dexamethasone for the GR, and aldosterone for the MR. Sources: [2][1][3][67][58]

Progestogenic activity

Drospirenone is an agonist of the PR, the biological target of progestogens like progesterone.[1][65] It has about 35% of the affinity of promegestone for the PR and about 19 to 70% of the affinity of progesterone for the PR.[1][2][58] Drospirenone has antigonadotropic and functional antiestrogenic effects as a result of PR activation.[1][65] The ovulation-inhibiting dosage of drospirenone is 2 to 3 mg/day.[68][69][1][70] Inhibition of ovulation occurred in about 90% of women at a dose of 0.5 to 2 mg/day and in 100% of women at a dose of 3 mg/day.[71] The total endometrial transformation dose of drospirenone is about 50 mg per cycle, whereas its daily dose is 2 mg for partial transformation and 4 to 6 mg for full transformation.[1][72][71] The medication acts as a contraceptive by activating the PR, which suppresses the secretion of luteinizing hormone, inhibits ovulation, and alters the cervical membrane and endometrium.[73][4]

Due to its antigonadotropic effects, drospirenone inhibits the secretion of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and suppresses gonadal sex hormone production, including of estradiol, progesterone, and testosterone.[1][74][2] Drospirenone alone at 4 mg/day has been found to suppress estradiol levels in premenopausal women to about 40 to 80 pg/mL depending on the time of the cycle.[74] No studies of the antigonadotropic effects of drospirenone or its influence on hormone levels appear to have been conducted in men.[75][76][77] In male cynomolgus monkeys however, 4 mg/kg/day oral drospirenone strongly suppressed testosterone levels.[65]

Antimineralocorticoid activity

Drospirenone is an antagonist of the MR, the biological target of mineralocorticoids like aldosterone, and hence is an antimineralocorticoid.[65] It has about 100 to 500% of the affinity of aldosterone for the MR and about 50 to 230% of the affinity of progesterone for the MR.[1][2][67][58] Drospirenone is about 5.5 to 11 times more potent as an antimineralocorticoid than spironolactone in animals.[65][71][78] Accordingly, 3 to 4 mg drospirenone is said to be equivalent to about 20 to 25 mg spironolactone in terms of antimineralocorticoid activity.[79][4] It has been said that the pharmacological profile of drospirenone more closely resembles that of progesterone than other progestins due to its antimineralocorticoid activity.[65] Drospirenone is the only clinically used progestogen with prominent antimineralocorticoid activity besides progesterone.[1] For comparison to progesterone, a 200 mg dose of oral progesterone is considered to be approximately equivalent in antimineralocorticoid effect to a 25 to 50 mg dose of spironolactone.[80] Both drospirenone and progesterone are actually weak partial agonists of the MR in the absence of mineralocorticoids.[3][2][58]

Due to its antimineralocorticoid activity, drospirenone increases natriuresis, decreases water retention and blood pressure, and produces compensatory increases in plasma renin activity as well as circulating levels and urinary excretion of aldosterone.[2][81][1] This has been shown to occur at doses of 2 to 4 mg/day.[2] Similar effects occur during the luteal phase of the menstrual cycle due to increased progesterone levels and the resulting antagonism of the MR.[2] Estrogens, particularly ethinylestradiol, activate liver production of angiotensinogen and increase levels of angiotensinogen and angiotensin II, thereby activating the renin–angiotensin–aldosterone system.[2][1] As a result, they can produce undesirable side effects including increased sodium excretion, water retention, weight gain, and increased blood pressure.[2] Progesterone and drospirenone counteract these undesirable effects via their antimineralocorticoid activity.[2] Accumulating research indicates that antimineralocorticoids like drospirenone and spironolactone may also have positive effects on adipose tissue and metabolic health.[82][83]

Antiandrogenic activity

Drospirenone is an antagonist of the AR, the biological target of androgens like testosterone and dihydrotestosterone (DHT).[1][2] It has about 1 to 65% of the affinity of the synthetic anabolic steroid metribolone for the AR.[1][2][3][58] The medication is more potent as an antiandrogen than spironolactone, but is less potent than cyproterone acetate, with about 30% of its antiandrogenic activity in animals.[1][84][65][71] Progesterone displays antiandrogenic activity in some assays similarly to drospirenone,[2] although this issue is controversial and many researchers regard progesterone as having no significant antiandrogenic activity.[85][1][3]

Drospirenone shows antiandrogenic effects on the serum lipid profile, including higher HDL cholesterol and triglyceride levels and lower LDL cholesterol levels, at a dose of 3 mg/day in women.[2] The medication does not inhibit the effects of ethinylestradiol on sex hormone-binding globulin (SHBG) and serum lipids, in contrast to androgenic progestins like levonorgestrel but similarly to other antiandrogenic progestins like cyproterone acetate.[2][1][70] SHBG levels are significantly higher with ethinylestradiol and cyproterone acetate than with ethinylestradiol and drospirenone, owing to the more potent antiandrogenic activity of cyproterone acetate relative to drospirenone.[86] Androgenic progestins like levonorgestrel have been found to inhibit the procoagulatory effects of estrogens like ethinylestradiol on hepatic synthesis of coagulation factors, whereas this may occur less or not at all with weakly androgenic progestins like desogestrel and antiandrogenic progestins like drospirenone.[8][56][52][53][54][55]

Other activity

Drospirenone stimulates the proliferation of MCF-7 breast cancer cells in vitro, an action that is independent of the classical PRs and is instead mediated via the progesterone receptor membrane component-1 (PGRMC1).[87] Certain other progestins act similarly in this assay, whereas progesterone acts neutrally.[87] It is unclear if these findings may explain the different risks of breast cancer observed with progesterone and progestins in clinical studies.[62]



The oral bioavailability of drospirenone is between 66 and 85%.[1][2][3] Peak levels occur 1 to 6 hours after an oral dose.[1][2][4][78] Levels are about 27 ng/mL after a single 4 mg dose.[4] There is 1.5- to 2-fold accumulation in drospirenone levels with continuous administration, with steady-state levels of drospirenone achieved after 7 to 10 days of administration.[1][4][2] Peak levels of drospirenone at steady state with 4 mg/day drospirenone are about 41 ng/mL.[4] With the combination of 30 μg/day ethinylestradiol and 3 mg/day drospirenone, peak levels of drospirenone after a single dose are 35 ng/mL, and levels at steady state are 60 to 87 ng/mL at peak and 20 to 25 ng/mL at trough.[2][1] The pharmacokinetics of oral drospirenone are linear with a single dose across a dose range of 1 to 10 mg.[4][2] Intake of drospirenone with food does not influence the absorption of drospirenone.[4]


The distribution half-life of drospirenone is about 1.6 to 2 hours.[2][1] The apparent volume of distribution of drospirenone is approximately 4 L/kg.[4] The plasma protein binding of drospirenone is 95 to 97%.[4][1] It is bound to albumin and 3 to 5% circulates freely or unbound.[4][1] Drospirenone has no affinity for sex hormone-binding globulin (SHBG) or corticosteroid-binding globulin (CBG), and hence is not bound by these plasma proteins in the circulation.[1]


The metabolism of drospirenone is extensive.[2] It is metabolized into the acid form of drospirenone by opening of its lactone ring.[1][4] The medication is also metabolized by reduction of its double bond between the C4 and C5 positions and subsequent sulfation.[1][4] The two major metabolites of drospirenone are drospirenone acid and 4,5-dihydrodrospirenone 3-sulfate, and are both formed independently of the cytochrome P450 system.[4][2] Neither of these metabolites are known to be pharmacologically active.[4] Drospirenone also undergoes oxidative metabolism by CYP3A4.[4][2][5][6]


Drospirenone is excreted in urine and feces, with slightly more excreted in feces than in urine.[4] Only trace amounts of unchanged drospirenone can be found in urine and feces.[4] At least 20 different metabolites can be identified in urine and feces.[2] Drospirenone and its metabolites are excreted in urine about 38% as glucuronide conjugates, 47% as sulfate conjugates, and less than 10% in unconjugated form.[2] In feces, excretion is about 17% glucuronide conjugates, 20% sulfate conjugates, and 33% unconjugated.[2]

The elimination half-life of drospirenone is between 25 and 33 hours.[4][2][1] The half-life of drospirenone is unchanged with repeated administration.[4] Elimination of drospirenone is virtually complete 10 days after the last dose.[2][4]


Chemical structures of spirolactones
The image above contains clickable links
Chemical structures of progesterone and spirolactones (steroid-17α-spirolactones).

Drospirenone, also known as 1,2-dihydrospirorenone or as 17β-hydroxy-6β,7β:15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21-carboxylic acid, γ-lactone, is a synthetic steroidal 17α-spirolactone, or more simply a spirolactone.[7][88] It is an analogue of other spirolactones like spironolactone, canrenone, and spirorenone.[7][88] Drospirenone differs structurally from spironolactone only in that the C7α acetylthio substitution of spironolactone has been removed and two methylene groups have been substituted in at the C6β–7β and C15β–16β positions.[89]

Spirolactones like drospirenone and spironolactone are derivatives of progesterone, which likewise has progestogenic and antimineralocorticoid activity.[90][91][92] The loss of the C7α acetylthio group of spironolactone, a compound with negligible progestogenic activity,[93][94] appears to be involved in the restoration of progestogenic activity in drospirenone, as SC-5233, the analogue of spironolactone without a C7α substitution, has potent progestogenic activity similarly to drospirenone.[95]


Drospirenone was patented in 1976 and introduced for medical use in 2000.[11][12] Schering AG of Germany has been granted several patents on the production of drospirenone, including WIPO and US patents, granted in 1998 and 2000, respectively.[96][97] It was introduced for medical use in combination with ethinylestradiol as a combined birth control pill in 2000.[11] Drospirenone is sometimes described as a "fourth-generation" progestin based on its time of introduction.[13][14] The medication was approved for use in menopausal hormone therapy in combination with estradiol in 2005.[21] Drospirenone was introduced for use as a progestogen-only birth control pill in 2019.[18]

Society and culture


In the U.S. the cost of this medication is about $197 (USD) for 28 tablets (4 mg)[98]

Generic names

Drospirenone is the generic name of the drug and its INN, USAN, BAN, and JAN, while drospirénone is its DCF.[7] Its name is a shortened form of the name 1,2-dihydrospirorenone or dihydrospirenone.[7][88] Drospirenone is also known by its developmental code names SH-470 and ZK-30595 (alone), BAY 86-5300, BAY 98-7071, and SH-T-00186D (in combination with ethinylestradiol), and BAY 86-4891 (in combination with estradiol).[7][88][99][100][101][102]

Brand names

Drospirenone is marketed in combination with an estrogen under a variety of brand names throughout the world.[7] Among others, it is marketed in combination with ethinylestradiol under the brand names Yasmin and Yaz and in combination with estradiol under the brand name Angeliq.[7]


Drospirenone is marketed widely throughout the world.[7]


Drospirenone has been categorized as a "fourth-generation" progestin.[58]


Many lawsuits have been filed against Bayer, the manufacturer of drospirenone, due to the higher risk of venous thromboembolism (VTE) that has been observed with combined birth control pills containing drospirenone and certain other progestins relative to the risk with levonorgestrel-containing combined birth control pills.[48]

In July 2012, Bayer notified its stockholders that there were more than 12,000 such lawsuits against the company involving Yaz, Yasmin, and other birth control pills with drospirenone.[103] They also noted that the company by then had settled 1,977 cases for US$402.6 million, for an average of US$212,000 per case, while setting aside US$610.5 million to settle the others.[103]

As of July 17, 2015, there have been at least 4,000 lawsuits and claims still pending regarding VTE related to drospirenone.[104] This is in addition to around 10,000 claims that Bayer has already settled without admitting liability.[104] These claims of VTE have amounted to US$1.97 billion.[104] Bayer also reached a settlement for arterial thromboembolic events, including stroke and heart attacks, for US$56.9 million.[104]


Drospirenone is under development by Mithra Pharmaceuticals in combination with estetrol (tentative brand name Estelle) as a combined birth control pill for prevention of pregnancy in women.[105] As of October 2019, it is in phase III clinical trials.[105]

A combination of ethinylestradiol, drospirenone, and prasterone is under development by Pantarhei Bioscience as a combined birth control pill for prevention of pregnancy in women.[106] It includes prasterone (dehydroepiandrosterone; DHEA), an oral androgen prohormone, to replace testosterone and avoid testosterone deficiency caused by suppression of testosterone by ethinylestradiol and drospirenone.[106] As of August 2018, the formulation is in phase II/III clinical trials.[106]

Drospirenone has been suggested for potential use as a progestin in male hormonal contraception.[75]

Drospirenone has been studied in forms for parenteral administration.[107][108][109][110]

See also


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 1.24 1.25 1.26 1.27 1.28 1.29 1.30 1.31 1.32 1.33 1.34 1.35 1.36 1.37 Kuhl, H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (sup1): 3–63. doi:10.1080/13697130500148875. ISSN 1369-7137. PMID 16112947. S2CID 24616324.
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 2.24 2.25 2.26 2.27 2.28 2.29 2.30 2.31 2.32 2.33 Krattenmacher, Rolf (2000). "Drospirenone: pharmacology and pharmacokinetics of a unique progestogen". Contraception. 62 (1): 29–38. doi:10.1016/S0010-7824(00)00133-5. ISSN 0010-7824. PMID 11024226.
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 Stanczyk FZ, Hapgood JP, Winer S, Mishell DR (April 2013). "Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects". Endocr. Rev. 34 (2): 171–208. doi:10.1210/er.2012-1008. PMC 3610676. PMID 23238854.
  4. 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 4.19 4.20 4.21 4.22 4.23 4.24 4.25 4.26 4.27 4.28 4.29 4.30 4.31 4.32 4.33 4.34 4.35 4.36 4.37 4.38 4.39 4.40 4.41 "Drospirenone tablets, for oral use" (PDF). FDA. Archived (PDF) from the original on 8 November 2020. Retrieved 12 November 2019.
  5. 5.0 5.1 Bachmann, Gloria (2009). "Drospirenone/ethinyl estradiol 3 mg/20 μg (24/4 day regimen): hormonal contraceptive choices – use of a fourth-generation progestin". Patient Preference and Adherence. 3: 259–64. doi:10.2147/PPA.S3901. ISSN 1177-889X. PMC 2778416. PMID 19936169.
  6. 6.0 6.1 Wiesinger, Herbert; Berse, Matthias; Klein, Stefan; Gschwend, Simone; Höchel, Joachim; Zollmann, Frank S.; Schütt, Barbara (2015). "Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol". British Journal of Clinical Pharmacology. 80 (6): 1399–1410. doi:10.1111/bcp.12745. ISSN 0306-5251. PMC 4693482. PMID 26271371.
  7. 7.00 7.01 7.02 7.03 7.04 7.05 7.06 7.07 7.08 7.09 7.10 "Drospirenone". Archived from the original on 2020-11-29. Retrieved 2021-01-05.
  8. 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 8.9 Han L, Jensen JT (December 2015). "Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?". Obstet. Gynecol. Clin. North Am. 42 (4): 683–98. doi:10.1016/j.ogc.2015.07.007. PMID 26598309.
  9. Oelkers W (December 2000). "Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone". Eur J Contracept Reprod Health Care. 5 Suppl 3: 17–24. PMID 11246598.
  10. Oelkers W (December 2002). "Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone". Eur J Contracept Reprod Health Care. 7 Suppl 3: 19–26, discussion 42–3. PMID 12659403.
  11. 11.0 11.1 11.2 Enrique Ravina (11 January 2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley & Sons. pp. 193–. ISBN 978-3-527-32669-3.
  12. 12.0 12.1 Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 459. ISBN 9783527607495. Archived from the original on 2021-04-18. Retrieved 2021-01-05.
  13. 13.0 13.1 Robert Anthony Hatcher; Anita L. Nelson, M.D. (2007). Contraceptive Technology. Ardent Media. pp. 196–. ISBN 978-1-59708-001-9. Archived from the original on 2021-08-29. Retrieved 2021-01-05.
  14. 14.0 14.1 James Q. Del Rosso; Joshua A. Zeichner (20 April 2016). Advances in Acne Management, An Issue of Dermatologic Clinics, E-Book. Elsevier Health Sciences. pp. 160–. ISBN 978-0-323-41753-2. Archived from the original on 29 August 2021. Retrieved 5 January 2021.
  15. "Generic Yasmin Availability". Archived from the original on 2021-01-16. Retrieved 2021-01-05.
  16. "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
  17. "Drospirenone; Ethinyl Estradiol - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.
  18. 18.0 18.1 18.2 "Drospirenone - Exeltis USA - AdisInsight". Archived from the original on 2020-01-26. Retrieved 2021-01-05.
  19. 19.0 19.1 "Drospirenone/ethinylestradiol low-dose - Bayer HealthCare Pharmaceuticals - AdisInsight". adisinsight.springer.com. Archived from the original on 2019-12-23. Retrieved 2021-01-05.
  20. Cerner Multum, Inc. (June 11, 2012). "drospirenone and ethinyl estradiol". Auckland, New Zealand: Drugs.com. Archived from the original on December 5, 2011. Retrieved October 24, 2011.
  21. 21.0 21.1 21.2 "Estradiol/drospirenone - Bayer HealthCare Pharmaceuticals - AdisInsight". adisinsight.springer.com. Archived from the original on 2018-07-20. Retrieved 2021-01-05.
  22. "ANGELIQ Tablets" (PDF). Food and Drug Administration. Archived (PDF) from the original on 2021-04-05. Retrieved 2021-01-05.
  23. Maclennan, A. H.; Broadbent, J. L.; Lester, S.; Moore, V. (18 October 2004). "Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes". The Cochrane Database of Systematic Reviews (4): CD002978. doi:10.1002/14651858.CD002978.pub2. ISSN 1469-493X. PMC 7004247. PMID 15495039.
  24. Torgerson, D. J.; Bell-Syer, S. E. (13 June 2001). "Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials". JAMA. 285 (22): 2891–2897. doi:10.1001/jama.285.22.2891. ISSN 0098-7484. PMID 11401611. S2CID 25078579.
  25. 25.0 25.1 Whitehead M (March 2006). "Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data". J Br Menopause Soc. 12 Suppl 1: 4–7. doi:10.1258/136218006775992185. PMID 16513012. S2CID 38095916.
  26. Majumder A, Sanyal D (2017). "Outcome and preferences in male-to-female subjects with gender dysphoria: Experience from Eastern India". Indian J Endocrinol Metab. 21 (1): 21–25. doi:10.4103/2230-8210.196000. PMC 5240066. PMID 28217493.
  27. Majumder, Anirban; Chatterjee, Sudip; Maji, Debasis; Roychaudhuri, Soumyabrata; Ghosh, Sujoy; Selvan, Chitra; George, Belinda; Kalra, Pramila; Maisnam, Indira; Sanyal, Debmalya (2020). "IDEA group consensus statement on medical management of adult gender incongruent individuals seeking gender reaffirmation as female". Indian Journal of Endocrinology and Metabolism. 24 (2): 128–135. doi:10.4103/ijem.IJEM_593_19. ISSN 2230-8210. PMC 7333765. PMID 32699777.
  28. Lanza di Scalea, Teresa (June 2017). "Premenstrual Dysphoric Disorder". Psychiatric Clinics of North America. 40 (2): 201–206. doi:10.1016/j.psc.2017.01.002. PMID 28477648.
  29. Lopez LM, Kaptein AA, Helmerhorst FM (February 2012). "Oral contraceptives containing drospirenone for premenstrual syndrome". Cochrane Database Syst Rev (2): CD006586. doi:10.1002/14651858.CD006586.pub4. PMID 22336820.
  30. Christiansen C (October 2005). "Effects of drospirenone/estrogen combinations on bone metabolism". Climacteric. 8 Suppl 3: 35–41. doi:10.1080/13697130500330283. PMID 16203654. S2CID 42803561.
  31. 31.0 31.1 Archer DF (February 2007). "Drospirenone and estradiol: a new option for the postmenopausal woman". Climacteric. 10 Suppl 1: 3–10. doi:10.1080/13697130601114859. PMID 17364592. S2CID 9221524.
  32. 32.0 32.1 "Drospirenone in HRT?". Drug Ther Bull. 47 (4): 41–4. April 2009. doi:10.1136/dtb.2009.03.0011. PMID 19357298. S2CID 1909717.
  33. Foidart JM, Faustmann T (December 2007). "Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen". Gynecol. Endocrinol. 23 (12): 692–9. doi:10.1080/09513590701582323. PMID 18075844. S2CID 12572825.
  34. "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Archived from the original on 16 November 2016. Retrieved 23 December 2019.
  35. Research, Center for Drug Evaluation and. "Drug Safety and Availability - FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone". www.fda.gov. Archived from the original on 2017-11-02. Retrieved 2017-11-07.
  36. "Archive copy" (PDF). Archived (PDF) from the original on 2021-04-02. Retrieved 2021-01-05.{{cite web}}: CS1 maint: archived copy as title (link)
  37. "Ethinylestradiol/drospirenone - AdisInsight". adisinsight.springer.com. Archived from the original on 2021-08-28. Retrieved 2021-01-05.
  38. "Ethinylestradiol/drospirenone/folic acid - AdisInsight". adisinsight.springer.com. Archived from the original on 2019-12-23. Retrieved 2021-01-05.
  39. "Archive copy" (PDF). Archived (PDF) from the original on 2021-03-30. Retrieved 2021-01-05.{{cite web}}: CS1 maint: archived copy as title (link)
  40. "Yaz" (PDF). Archived (PDF) from the original on December 26, 2019. Retrieved October 31, 2017.
  41. 41.0 41.1 41.2 Bayer (March 25, 2013). "Summary of Product Characteristics (SPC): Yasmin". London: electronic Medicines Compendium (eMC), Datapharm. Archived from the original on April 24, 2014. Retrieved April 24, 2014. 4.3. Contraindications: • Severe chronic kidney disease or acute kidney failure. • Presence or history of severe hepatic disease as long as liver function values have not returned to normal.
  42. 42.0 42.1 Bayer (April 10, 2012). "Yasmin full prescribing information" (PDF). Silver Spring, Md.: Food and Drug Administration (FDA). Archived (PDF) from the original on April 25, 2012. Retrieved April 14, 2012. 4. Contraindications: • Renal impairment. • Adrenal insufficiency. • Liver disease.
  43. Nelson, Anita L.; Cwiak, Carrie (2011). "Combined oral contraceptives (COCs)". In Hatcher, Robert A.; Trussell, James; Nelson, Anita L.; Cates, Willard Jr.; Kowal, Deborah; Policar, Michael S. (eds.). Contraceptive Technology (20th revised ed.). New York: Ardent Media. pp. 249–341. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734.
  44. 44.0 44.1 Heit JA, Spencer FA, White RH (2016). "The epidemiology of venous thromboembolism". J. Thromb. Thrombolysis. 41 (1): 3–14. doi:10.1007/s11239-015-1311-6. PMC 4715842. PMID 26780736.
  45. 45.0 45.1 45.2 45.3 45.4 Bateson D, Butcher BE, Donovan C, Farrell L, Kovacs G, Mezzini T, Raynes-Greenow C, Pecoraro G, Read C, Baber R (2016). "Risk of venous thromboembolism in women taking the combined oral contraceptive: A systematic review and meta-analysis". Aust Fam Physician. 45 (1): 59–64. PMID 27051991. Archived from the original on 2021-04-08. Retrieved 2021-01-05.
  46. 46.0 46.1 "FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone". April 27, 2019. Archived from the original on 2019-04-27.
  47. Vinogradova Y, Coupland C, Hippisley-Cox J (January 2019). "Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases". BMJ. 364: k4810. doi:10.1136/bmj.k4810. PMC 6326068. PMID 30626577.
  48. 48.0 48.1 48.2 Batur P, Casey PM (February 2017). "Drospirenone Litigation: Does the Punishment Fit the Crime?". J Womens Health (Larchmt). 26 (2): 99–102. doi:10.1089/jwh.2016.6092. PMID 27854556.
  49. 49.0 49.1 Sitruk-Ware R (November 2016). "Hormonal contraception and thrombosis". Fertil. Steril. 106 (6): 1289–1294. doi:10.1016/j.fertnstert.2016.08.039. PMID 27678035.
  50. Oedingen C, Scholz S, Razum O (May 2018). "Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: The role of the progestogen type and estrogen dose". Thromb. Res. 165: 68–78. doi:10.1016/j.thromres.2018.03.005. PMID 29573722.
  51. Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME (June 2018). "A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception". Int J Gynaecol Obstet. 141 (3): 287–294. doi:10.1002/ijgo.12455. PMC 5969307. PMID 29388678.
  52. 52.0 52.1 Wiegratz I, Kuhl H (September 2006). "Metabolic and clinical effects of progestogens". Eur J Contracept Reprod Health Care. 11 (3): 153–61. doi:10.1080/13625180600772741. PMID 17056444. S2CID 27088428.
  53. 53.0 53.1 Kuhl H (May 1996). "Effects of progestogens on haemostasis". Maturitas. 24 (1–2): 1–19. doi:10.1016/0378-5122(96)00994-2. PMID 8794429.
  54. 54.0 54.1 Sitruk-Ware R, Nath A (February 2013). "Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills". Best Pract. Res. Clin. Endocrinol. Metab. 27 (1): 13–24. doi:10.1016/j.beem.2012.09.004. PMID 23384742.
  55. 55.0 55.1 Nelson AL (2015). "An update on new orally administered contraceptives for women". Expert Opin Pharmacother. 16 (18): 2759–72. doi:10.1517/14656566.2015.1100173. PMID 26512437. S2CID 207481206.
  56. 56.0 56.1 56.2 Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G (October 2017). "Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis". Expert Rev Clin Pharmacol. 10 (10): 1129–1144. doi:10.1080/17512433.2017.1356718. PMID 28712325. S2CID 205931204.
  57. 57.0 57.1 Simoncini T, Genazzani AR (February 2010). "A review of the cardiovascular and breast actions of drospirenone in preclinical studies". Climacteric. 13 (1): 22–33. doi:10.3109/13697130903437375. PMID 19938948. S2CID 4306359.
  58. 58.0 58.1 58.2 58.3 58.4 58.5 58.6 58.7 58.8 58.9 Africander D, Verhoog N, Hapgood JP (June 2011). "Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception". Steroids. 76 (7): 636–52. doi:10.1016/j.steroids.2011.03.001. PMID 21414337. S2CID 23630452.
  59. Palacios S, Mejía A (November 2016). "Progestogen safety and tolerance in hormonal replacement therapy". Expert Opin Drug Saf. 15 (11): 1515–1525. doi:10.1080/14740338.2016.1223041. PMID 27548404. S2CID 31497860.
  60. Caglayan EK, Caglayan K, Alkis I, Arslan E, Okur A, Banli O, Engin-Ustün Y (August 2015). "Factors Associated with Mammographic Density in Postmenopausal Women". J Menopausal Med. 21 (2): 82–8. doi:10.6118/jmm.2015.21.2.82. PMC 4561745. PMID 26357645.
  61. Hirschberg AL, Tani E, Brismar K, Lundström E (August 2019). "Effects of drospirenone and norethisterone acetate combined with estradiol on mammographic density and proliferation of breast epithelial cells-A prospective randomized trial". Maturitas. 126: 18–24. doi:10.1016/j.maturitas.2019.04.205. PMID 31239112.
  62. 62.0 62.1 62.2 62.3 Trabert B, Sherman ME, Kannan N, Stanczyk FZ (September 2019). "Progesterone and breast cancer". Endocr. Rev. 41 (2): 320–344. doi:10.1210/endrev/bnz001. PMC 7156851. PMID 31512725.
  63. Collaborative Group on Hormonal Factors in Breast Cancer (September 2019). "Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence". Lancet. 394 (10204): 1159–1168. doi:10.1016/S0140-6736(19)31709-X. PMC 6891893. PMID 31474332.
  64. Sturdee DW (2013). "Are progestins really necessary as part of a combined HRT regimen?". Climacteric. 16 Suppl 1: 79–84. doi:10.3109/13697137.2013.803311. PMID 23651281. S2CID 21894200.
  65. 65.0 65.1 65.2 65.3 65.4 65.5 65.6 65.7 65.8 65.9 Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E (1995). "Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity". Ann. N. Y. Acad. Sci. 761 (3): 311–35. Bibcode:1995NYASA.761..311M. doi:10.1111/j.1749-6632.1995.tb31386.x. PMID 7625729. S2CID 36861309.
  66. Fuhrmann, Ulrike; Krattenmacher, Rolf; Slater, Emily P.; Fritzemeier, Karl-Heinrich (1996). "The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential". Contraception. 54 (4): 243–251. doi:10.1016/S0010-7824(96)00195-3. ISSN 0010-7824. PMID 8922878.
  67. 67.0 67.1 Hapgood JP, Africander D, Louw R, Ray RM, Rohwer JM (July 2014). "Potency of progestogens used in hormonal therapy: toward understanding differential actions". J. Steroid Biochem. Mol. Biol. 142: 39–47. doi:10.1016/j.jsbmb.2013.08.001. PMID 23954501. S2CID 12142015.
  68. Bastianelli C, Farris M, Rosato E, Brosens I, Benagiano G (November 2018). "Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation". Expert Rev Clin Pharmacol. 11 (11): 1085–1098. doi:10.1080/17512433.2018.1536544. PMID 30325245. S2CID 53246678.
  69. Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B (December 2011). "Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide". Contraception. 84 (6): 549–57. doi:10.1016/j.contraception.2011.04.009. PMID 22078182.
  70. 70.0 70.1 Kuhl H (2011). "Pharmacology of Progestogens" (PDF). J Reproduktionsmed Endokrinol. 8 (1): 157–177. Archived (PDF) from the original on 2016-10-11. Retrieved 2021-01-05.
  71. 71.0 71.1 71.2 71.3 Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A (November 2003). "Conception and pharmacodynamic profile of drospirenone". Steroids. 68 (10–13): 891–905. doi:10.1016/j.steroids.2003.08.008. PMID 14667981. S2CID 41756726.
  72. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH (December 2003). "Classification and pharmacology of progestins". Maturitas. 46 Suppl 1: S7–S16. doi:10.1016/j.maturitas.2003.09.014. PMID 14670641.
  73. "Drospirenone". pubchem.ncbi.nlm.nih.gov. Archived from the original on 2021-03-02. Retrieved 2021-01-05.
  74. 74.0 74.1 Hadji P, Colli E, Regidor PA (December 2019). "Bone health in estrogen-free contraception". Osteoporos Int. 30 (12): 2391–2400. doi:10.1007/s00198-019-05103-6. PMC 7203087. PMID 31446440.
  75. 75.0 75.1 Cornia, Paul B; Anawalt, Bradley D (2005). "Male hormonal contraceptives: a potentially patentable and profitable product". Expert Opinion on Therapeutic Patents. 15 (12): 1727–1737. doi:10.1517/13543776.15.12.1727. ISSN 1354-3776. S2CID 83941717.
  76. Nieschlag E (2010). "Clinical trials in male hormonal contraception" (PDF). Contraception. 82 (5): 457–70. doi:10.1016/j.contraception.2010.03.020. PMID 20933120. Archived (PDF) from the original on 2020-12-05. Retrieved 2021-01-05.
  77. Nieschlag, Eberhard; Behre, Hermann M.; Nieschlag, Eberhard; Behre, Hermann M.; Nieschlag, Susan (2012). "The essential role of testosterone in hormonal male contraception". In Nieschlag, Eberhard; Behre, Hermann M; Nieschlag, Susan (eds.). Testosterone. pp. 470–493. doi:10.1017/CBO9781139003353.023. ISBN 9781139003353.
  78. 78.0 78.1 Stanczyk, Frank Z. (2007). "Structure –Function Relationships, Pharmacokinetics, and Potency of Orally and Parenterally Administered Progestogens". Treatment of the Postmenopausal Woman. pp. 779–798. doi:10.1016/B978-012369443-0/50067-3. ISBN 9780123694430.
  79. Hermann P.G. Schneider; Frederick Naftolin (22 September 2004). Climacteric Medicine - Where Do We Go?: Proceedings of the 4th Workshop of the International Menopause Society. CRC Press. pp. 133–. ISBN 978-0-203-02496-6.
  80. Simon JA (December 1995). "Micronized progesterone: vaginal and oral uses". Clinical Obstetrics and Gynecology. 38 (4): 902–14. doi:10.1097/00003081-199538040-00024. PMID 8616985.
  81. Genazzani, Andrea R.; Mannella, Paolo; Simoncini, Tommaso (February 2007). "Drospirenone and its antialdosterone properties". Climacteric. 10 (Supplement 1): 11–18. doi:10.1080/13697130601114891. PMID 17364593. S2CID 24872884. Archived from the original on April 24, 2014. Retrieved November 26, 2011.
  82. Infante, Marco; Armani, Andrea; Marzolla, Vincenzo; Fabbri, Andrea; Caprio, Massimiliano (2019). "Adipocyte Mineralocorticoid Receptor". Vitamins and Hormones. Elsevier. 109: 189–209. doi:10.1016/bs.vh.2018.10.005. ISBN 9780128177822. ISSN 0083-6729. PMID 30678856.
  83. Giordano A, Frontini A, Cinti S (June 2016). "Convertible visceral fat as a therapeutic target to curb obesity". Nat Rev Drug Discov. 15 (6): 405–24. doi:10.1038/nrd.2016.31. PMID 26965204. S2CID 2632187.
  84. Sitruk-Ware R, Husmann F, Thijssen JH, Skouby SO, Fruzzetti F, Hanker J, Huber J, Druckmann R (September 2004). "Role of progestins with partial antiandrogenic effects". Climacteric. 7 (3): 238–54. doi:10.1080/13697130400001307. PMID 15669548. S2CID 23112620.
  85. Yeh YT, Chang CW, Wei RJ, Wang SN (2013). "Progesterone and related compounds in hepatocellular carcinoma: basic and clinical aspects". Biomed Res Int. 2013: 290575. doi:10.1155/2013/290575. PMC 3581253. PMID 23484104.
  86. Schindler, Adolf E. (2015). "Hormonal Contraceptives: Progestogen and Thrombotic Risk". Frontiers in Gynecological Endocrinology. ISGE Series. pp. 69–75. doi:10.1007/978-3-319-09662-9_8. ISBN 978-3-319-09661-2. ISSN 2197-8735.
  87. 87.0 87.1 Neubauer H, Ma Q, Zhou J, Yu Q, Ruan X, Seeger H, Fehm T, Mueck AO (October 2013). "Possible role of PGRMC1 in breast cancer development". Climacteric. 16 (5): 509–13. doi:10.3109/13697137.2013.800038. PMID 23758160. S2CID 29808177.
  88. 88.0 88.1 88.2 88.3 Martin Negwer; Hans-Georg Scharnow (4 October 2001). Organic-chemical drugs and their synonyms: (an international survey). Wiley-VCH. p. 2539. ISBN 978-3-527-30247-5.
  89. Howard J.A. Carp (9 April 2015). Progestogens in Obstetrics and Gynecology. Springer. pp. 115–. ISBN 978-3-319-14385-9. Archived from the original on 29 August 2021. Retrieved 5 January 2021.
  90. Ménard J (2004). "The 45-year story of the development of an anti-aldosterone more specific than spironolactone". Mol. Cell. Endocrinol. 217 (1–2): 45–52. doi:10.1016/j.mce.2003.10.008. PMID 15134800. S2CID 19701784. [Spironolactone] was synthesized after the demonstration of the natriuretic effect of progesterone (Landau et al., 1955).
  91. J. Larry Jameson; Leslie J. De Groot (18 May 2010). Endocrinology - E-Book: Adult and Pediatric. Elsevier Health Sciences. pp. 2401–. ISBN 978-1-4557-1126-0. Archived from the original on 20 August 2020. Retrieved 5 January 2021. [Spironolactone] is a potent antimineralocorticoid which was developed as a progestational analog [...]
  92. Aldosterone. Elsevier Science. 23 January 2019. p. 46. ISBN 978-0-12-817783-9. Archived from the original on 29 August 2021. Retrieved 5 January 2021. In addition to spironolactone, which is a derivative of progesterone [...]
  93. Hu X, Li S, McMahon EG, Lala DS, Rudolph AE (2005). "Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone". Mini Rev Med Chem. 5 (8): 709–18. doi:10.2174/1389557054553811. PMID 16101407.
  94. Nakajima ST, Brumsted JR, Riddick DH, Gibson M (1989). "Absence of progestational activity of oral spironolactone". Fertil. Steril. 52 (1): 155–8. doi:10.1016/s0015-0282(16)60807-5. PMID 2744183.
  95. Hertz R, Tullner WW (1958). "Progestational activity of certain steroid-17-spirolactones". Proc. Soc. Exp. Biol. Med. 99 (2): 451–2. doi:10.3181/00379727-99-24380. PMID 13601900. S2CID 20150966.
  96. WO patent 9806738, Mohr, Jörg-Thorsten & Klaus Nickisch, "PROCESS FOR PRODUCING DROSPIRENONE (6ss,7ss;15ss,16ss-DIMETHYLENE-3-OXO-17 alpha -PREGN-4-EN-21,17-CARBOLACTONE, DRSP), AS WELL AS 7 alpha -(3-HYDROXY-1-PROPYL)-6ss,7ss;15ss,16ss-DIMETHYLENE-5ss-ANDROSTANE-3ss,5,17ss-TRIOL (ZK 92836) AND 6ss,7ss;15ss,16ss-DIMETHYLENE-5ss HYDROXY-5-OXO-17 alpha -ANDROSTANE-21, 17-CARBOLACTONE", issued 1998-02-19, assigned to Shering AG 
  97. US patent 6121465, Mohr, Joerg-Thorston & Klaus Nickisch, "Process for production drospirenone and intermediate products of the process", issued 2000-09-19, assigned to Scheiring AG and Bayer Schering Pharma 
  98. "Prescription Price Comparison | Compare Drug Prices". www.wellrx.com. Archived from the original on 29 August 2021. Retrieved 29 March 2021.
  99. "Ethinylestradiol/drospirenone - AdisInsight". Archived from the original on 2021-08-28. Retrieved 2021-01-05.
  100. "Ethinylestradiol/drospirenone/folic acid - AdisInsight". Archived from the original on 2019-12-23. Retrieved 2021-01-05.
  101. "Drospirenone/ethinylestradiol low-dose - Bayer HealthCare Pharmaceuticals - AdisInsight". Archived from the original on 2019-12-23. Retrieved 2021-01-05.
  102. "Estradiol/drospirenone - Bayer HealthCare Pharmaceuticals - AdisInsight". Archived from the original on 2018-07-20. Retrieved 2021-01-05.
  103. 103.0 103.1 Feeley, Jef; Kresge, Naomi (July 31, 2012). "Bayer's Yasmin lawsuit settlements rise to $402.6 million". Bloomberg News. New York. Archived from the original on August 26, 2012. Retrieved November 11, 2012.
  104. 104.0 104.1 104.2 104.3 AG, Bayer. "Quarterly Reports of Bayer". www.bayer.com. Archived from the original on 2020-08-17. Retrieved 2021-01-05.
  105. 105.0 105.1 "Drospirenone/estetrol - Mithra Pharmaceuticals - AdisInsight". Archived from the original on 2021-04-13. Retrieved 2021-01-05.
  106. 106.0 106.1 106.2 "Drospirenone/estradiol/prasterone - ANI Pharmaceuticals/Pantarhei Bioscience - AdisInsight". adisinsight.springer.com. Archived from the original on 2019-12-23. Retrieved 2021-01-05.
  107. Nippe S, General S (September 2011). "Parenteral oil-based drospirenone microcrystal suspensions-evaluation of physicochemical stability and influence of stabilising agents". Int J Pharm. 416 (1): 181–8. doi:10.1016/j.ijpharm.2011.06.036. PMID 21729745.
  108. Nippe S, General S (November 2012). "Combination of injectable ethinyl estradiol and drospirenone drug-delivery systems and characterization of their in vitro release". Eur J Pharm Sci. 47 (4): 790–800. doi:10.1016/j.ejps.2012.08.009. PMID 22940138.
  109. Nippe S, Preuße C, General S (February 2013). "Evaluation of the in vitro release and pharmacokinetics of parenteral injectable formulations for steroids". Eur J Pharm Biopharm. 83 (2): 253–65. doi:10.1016/j.ejpb.2012.09.006. PMID 23116659.
  110. Nippe S, General S (April 2015). "Investigation of injectable drospirenone organogels with regard to their rheology and comparison to non-stabilized oil-based drospirenone suspensions". Drug Dev Ind Pharm. 41 (4): 681–91. doi:10.3109/03639045.2014.895375. PMID 24621345. S2CID 42932558.

Further reading

External links